TS-021

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: TS-021
• 英文别名: (2S,4S)-4-fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}pyrrolidine-2-carbonitrile monobenzenesulfonate；(2S,4S)-2-cyano-4-fluoro-1-[(2-hydroxy-1,1-dimethyl)ethylamino]acetylpyrrolidine benzenesulfonate salt；(2S,4S)-2-cyano-4-fluoro-1-[2-hydroxy-1,1-(dimethyl)ethylamino]acetylpyrrolidine benzensulphonate；(2S,4S)-4-fluoro-1-((1-hydroxy-2-methylpropan-2-yl)glycyl)pyrrolidine-2-carbonitrile benzenesulfonate；benzenesulfonic acid;(2S,4S)-4-fluoro-1-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile
• 化学式: C₆H₆O₃S*C₁₁H₁₈FN₃O₂
• 分子量: 401.459
• InChiKey: BMWITAUNXBHIPO-OZZZDHQUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.74
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (2S,4S)-4-fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}pyrrolidine-2-carbonitrile 、 苯磺酸 以 甲醇 、 异丙醚 为溶剂， 反应 2.45h， 生成 TS-021
  参考文献：
  名称：

  PROCESS FOR PRODUCTION OF CIS-4-FLUORO-L-PROLINE DERIVATIVES

  摘要：

  本发明提供了一种更安全的方法，用于在较温和的条件下且高产率地生产cis-4-氟-L-脯氨酸衍生物，以在工业规模下以低成本提供高纯度的产品。换句话说，本发明提供了一种生产cis-4-氟-L-脯氨酸衍生物的方法，包括将以下式[I]的trans-4-羟基-L-脯氨酸衍生物（其中R1代表α-氨基的保护基，R2代表羧基的保护基）与N,N-二乙基-N-(1,1,2,3,3,3-六氟丙基)胺在氢氟酸清除剂的存在下反应。

  公开号：

  EP1657237A1

文献信息

• ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT
  申请人：SCHWINK Lothar

  公开号：US20070197584A1

  公开（公告）日：2007-08-23

  The invention relates to aryl-substituted polycyclic amines of the formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof; where the symbols and radicals are explained in the description as well as to pharmaceutical compositions and medical treatments employing these compounds.

  该发明涉及公式I的芳基取代的多环胺，特别是双环胺，以及其生理耐受的盐和生理功能衍生物；其中符号和基团在描述中有解释，还涉及使用这些化合物的药物组合物和医疗治疗。
• Aryl-substituted heterocycles, process for their preparation and their use as medicaments
  申请人：Schwink Lothar

  公开号：US20050176710A1

  公开（公告）日：2005-08-11

  The invention relates to substituted aryl-substituted heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof, to process for their preparation and to their use as medicaments. Compounds of the Formula I in which the radicals have the stated meanings, the N-oxides thereof, and the physiologically tolerated salts thereof, and process for the preparation thereof are described. The compounds bring about for example a weight reduction in mammals and are suitable for example for the prevention and treatment of obesity and diabetes.

  该发明涉及取代芳基取代杂环化合物及其生理上可耐受的盐和生理功能衍生物，以及其制备方法和用作药物的用途。描述了式I中的化合物，其中基团具有陈述的含义，其N-氧化物以及生理上可耐受的盐，以及其制备方法。这些化合物例如可导致哺乳动物体重减轻，并且例如适用于肥胖和糖尿病的预防和治疗。
• Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040198786A1

  公开（公告）日：2004-10-07

  Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals The invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula 1, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  环烷基衍生物具有生物等效羧酸基团，其制备方法及其作为药物的用途。本发明涉及具有生物等效羧酸基团的环烷基衍生物及其生理上可接受的盐和生理功能衍生物。所描述的化合物具有下式1,1中所定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用障碍以及胰岛素抵抗相关的紊乱。
• 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209932A1

  公开（公告）日：2004-10-21

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  本发明涉及具有酸性、大多数是杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能衍生物。所描述的是式I中的化合物，其中基团如定义所示，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病。
• NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF
  申请人：BRUMMERHOP Harm

  公开号：US20070197623A1

  公开（公告）日：2007-08-23

  The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I) as further defined in the specification, to the physiologically compatible salts thereof, to a method for their production, and to their use as antidiabetics.

  本发明涉及一种代替氟基的吡唑烷基糖苷衍生物，其化学式为（I），在规范中进一步定义，其生理兼容盐的制备方法，以及它们作为抗糖尿病药物的用途。